Database : MEDLINE
Search on : D02.455.426.559.389.048.088 [DeCS Category]
References found : 77 [refine]
Displaying: 1 .. 10   in format [Large]

page 1 of 8 go to page                    

  1 / 77 MEDLINE  
              next record last record
select
to print
Photocopy
PubMed Central Full text
Full text
PMID:27372014
Author:Liu HM; Jiang F; Loo YM; Hsu S; Hsiang TY; Marcotrigiano J; Gale M
Address:Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington School of Medicine, 750 Republican St, Seattle, WA, USA; Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, No. 1, Changde St, Taipei City, Taiwan. Electro
Title:Regulation of Retinoic Acid Inducible Gene-I (RIG-I) Activation by the Histone Deacetylase 6.
Source:EBioMedicine; 9:195-206, 2016 Jul.
ISSN:2352-3964
Country of publication:Netherlands
Language:eng
Abstract:Retinoic acid inducible gene-I (RIG-I) is a cytosolic pathogen recognition receptor that initiates the immune response against many RNA viruses. Upon RNA ligand binding, RIG-I undergoes a conformational change facilitating its homo-oligomerization and activation that results in its translocation from the cytosol to intracellular membranes to bind its signaling adaptor protein, mitochondrial antiviral-signaling protein (MAVS). Here we show that RIG-I activation is regulated by reversible acetylation. Acetyl-mimetic mutants of RIG-I do not form virus-induced homo-oligomers, revealing that acetyl-lysine residues of the RIG-I repressor domain prevent assembly to active homo-oligomers. During acute infection, deacetylation of RIG-I promotes its oligomerization upon ligand binding. We identify histone deacetylase 6 (HDAC6) as the deacetylase that promotes RIG-I activation and innate antiviral immunity to recognize and restrict RNA virus infection.
Publication type:JOURNAL ARTICLE
Name of substance:0 (RNA, Small Interfering); 4T3C38J78L (Bufexamac); 77238-31-4 (Interferon-beta); EC 3.5.1.98 (Hdac6 protein, mouse); EC 3.5.1.98 (Histone Deacetylase 6); EC 3.5.1.98 (Histone Deacetylases); EC 3.6.1.- (Ddx58 protein, mouse); EC 3.6.4.13 (DEAD Box Protein 58)


  2 / 77 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text
PMID:25288472
Author:Dinkloh A; Worm M; Geier J; Schnuch A; Wollenberg A
Address:Department of Dermatology, Venereology and Allergy, Charité Universitätsmedizin, Berlin, Germany.
Title:Contact sensitization in patients with suspected cosmetic intolerance: results of the IVDK 2006-2011.
Source:J Eur Acad Dermatol Venereol; 29(6):1071-81, 2015 Jun.
ISSN:1468-3083
Country of publication:England
Language:eng
Abstract:BACKGROUND: Ingredients of leave-on cosmetics and body care products may sensitize. However, not every case of cosmetic intolerance is due to contact sensitization. OBJECTIVE: To describe the frequency of contact sensitization due to cosmetics in a large clinic population, and a possible particular allergen pattern. METHODS: Retrospective analysis of data from the Information Network of Departments of Dermatology, 2006-2011. RESULTS: Of 69 487 patients tested, 'cosmetics, creams, sunscreens' was the only suspected allergen source category in 10 124 patients (14.6%). A final diagnosis 'allergic contact dermatitis' was stated in 2658 of these patients (26.3%).Compared to a control group, there were significantly more reactions to fragrance mixes I and II, balsam of Peru, methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) and lanolin alcohols. No special pattern of fragrance sensitization could be identified. Among the preservatives, MI was by far the leading allergen, while sensitization to other widely used compounds like parabens or phenoxyethanol was rare. CONCLUSIONS: True allergic reactions to cosmetic ingredients are rarer than generally assumed. Limitation of exposure to MI in leave-on cosmetics and body care products is urgently needed.
Publication type:JOURNAL ARTICLE
Name of substance:0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Balsams); 0 (Cosmetics); 0 (Perfume); 0 (Preservatives, Pharmaceutical); 0 (Sunscreening Agents); 0 (Thiazoles); 229D0E1QFA (2-methyl-4-isothiazolin-3-one); 4T3C38J78L (Bufexamac); 8P5F881OCY (Peruvian balsam); DEL7T5QRPN (5-chloro-2-methyl-4-isothiazolin-3-one)


  3 / 77 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text
PMID:22881467
Author:Pan Y; Nixon R
Address:Occupational Dermatology Research and Education Centre, Skin and Cancer Foundation Inc., Melbourne, VIC 3053, Australia. yanpan_98@yahoo.com
Title:Allergic contact dermatitis to topical preparations of bufexamac.
Source:Australas J Dermatol; 53(3):207-10, 2012 Aug.
ISSN:1440-0960
Country of publication:Australia
Language:eng
Abstract:In Australia bufexamac is mainly used for pharmacist-initiated local treatment of various dermatoses. The European Medicines Agency's Committee for Medicinal Products for Human Use recently recommended that marketing authorisation for bufexamac-containing preparations be revoked throughout the European Union because of the risk of severe allergic contact dermatitis. We retrospectively reviewed the patch test database at the Skin and Cancer Foundation Inc. and identified 19 cases of positive reactions to bufexamac (5% petrolatum) from 451 people patch tested. The bufexamac reaction was deemed relevant to the presenting dermatitis in 13 of 19 (68%) patients. Bufexamac allergic contact dermatitis is under-reported in the English literature. We wish to emphasise the severity and the unusually polymorphic eruptions observed in some of the cases. Clinicians should consider the possibility of allergic contact dermatitis to bufexamac-containing preparations in all patients where there is a history of exposure, even if used for only a short time.
Publication type:JOURNAL ARTICLE
Name of substance:0 (Anti-Inflammatory Agents, Non-Steroidal); 4T3C38J78L (Bufexamac)


  4 / 77 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text
PMID:22828265
Author:Nakada T; Matsuzawa Y
Address:Division of Dermatology, Showa University Northern Yokohama Hospital, Kanagawa, Japan. tokio@med.showa-u.ac.jp
Title:Allergic contact dermatitis syndrome from bufexamac for nursing infant.
Source:Dermatitis; 23(4):185-6, 2012 Jul-Aug.
ISSN:2162-5220
Country of publication:United States
Language:eng
Publication type:JOURNAL ARTICLE
Name of substance:0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Glucocorticoids); 4T3C38J78L (Bufexamac); 9PHQ9Y1OLM (Prednisolone)


  5 / 77 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text
PMID:21950459
Author:Fukuda H; Sato Y; Usami N; Yokouchi Y; Mukai H
Title:Contact dermatitis caused by bufexamac sparing the eruption of herpes zoster.
Source:J Dermatol; 39(4):405-7, 2012 Apr.
ISSN:1346-8138
Country of publication:England
Language:eng
Publication type:CASE REPORTS; LETTER
Name of substance:0 (Anti-Inflammatory Agents, Non-Steroidal); 4T3C38J78L (Bufexamac)


  6 / 77 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text
PMID:21429689
Author:Seto Y; Ochi M; Igarashi N; Inoue R; Oishi A; Toida T; Yamada S; Onoue S
Address:Department of Pharmacokinetics and Pharmacodynamics and Global Center of Excellence (COE) Program, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.
Title:In vitro photobiochemical characterization of sulfobutylether-ß-cyclodextrin formulation of bufexamac.
Source:J Pharm Biomed Anal; 55(3):591-6, 2011 Jun 01.
ISSN:1873-264X
Country of publication:England
Language:eng
Abstract:The present study aimed to modulate the photoreactivity of bufexamac, with a focus on photostability and phototoxicity, by forming an inclusion complex with sulfobutylether-ß-cyclodextrin (SBECD). The photobiochemical properties of bufexamac were evaluated by reactive oxygen species (ROS) assay and using in vitro photogenotoxic assessment tools. To assess the inclusion properties of SBECD complex with bufexamac, a UV absorption spectroscopic study was also carried out. The influence of SBECD on the photoreactivity of bufexamac was analyzed by ROS assay and photostability test. From the photobiochemical data, superoxide generation from irradiated bufexamac indicated its photoreactivity; however, the photogenotoxic risk of bufexamac was negligible owing to low DNA-binding affinity and DNA-photocleaving activity. SBECD complex of bufexamac was formed, and the association constant of the complex was calculated to be 620M(-1). On the basis of the photochemical data on bufexamac co-existing with SBECD, ROS generation from irradiated bufexamac (200µM) was inhibited by SBECD at concentrations of over 20µM. The degradation constant of bufexamac in SBECD was decreased ca. 30% compared with that of bufexamac, suggesting improvement of its photostability. The phototoxic risk of bufexamac might be attenuated by SBECD complexation, and cyclodextrin inclusion complexes might be a useful approach for modulating the phototoxicity of drugs.
Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
Name of substance:0 (Reactive Oxygen Species); 0 (beta-Cyclodextrins); 2PP9364507 (SBE4-beta-cyclodextrin); 4T3C38J78L (Bufexamac); 9007-49-2 (DNA)


  7 / 77 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text
PMID:21392031
Author:Uter W; Schnuch A
Title:EMA revokes marketing authorization for bufexamac.
Source:Contact Dermatitis; 64(4):235-6, 2011 Apr.
ISSN:1600-0536
Country of publication:England
Language:eng
Publication type:LETTER
Name of substance:0 (Anti-Inflammatory Agents, Non-Steroidal); 4T3C38J78L (Bufexamac)


  8 / 77 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text
PMID:19093092
Author:Waltermann K; Marsch WCh; Kreft B
Address:Klinik für Dermatologie, Venerologie und Allergie, Universitätsklinikum Essen, Hufelandstrasse 55, 45122, Essen, Deutschland. katharina.waltermann@uk-essen.de
Title:Kontaktallergie durch Bufexamac unter dem Bild einer chronischen Pigmentpurpura. [Bufexamac-induced pigmented purpuric eruption].
Source:Hautarzt; 60(5):424-7, 2009 May.
ISSN:1432-1173
Country of publication:Germany
Language:ger
Abstract:We report on a case of a bufexamac-induced allergic contact dermatitis with hematogenous dissemination presenting with the clinical and histological picture of a pigmented purpuric eruption. To our knowledge this is the first report on a bufexamac-induced pigmented purpuric dermatosis. It represents a further example of the clinical variety of cutaneous side-effects caused by bufexamac.
Publication type:CASE REPORTS; ENGLISH ABSTRACT; JOURNAL ARTICLE
Name of substance:0 (Anti-Inflammatory Agents, Non-Steroidal); 4T3C38J78L (Bufexamac)


  9 / 77 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text
PMID:18828848
Author:Langan SM; Williams HC
Address:Centre of Evidence-based Dermatology, University of Nottingham, Nottingham, UK. sinead.langan@nottingham.ac.uk
Title:A systematic review of randomized controlled trials of treatments for inherited forms of epidermolysis bullosa.
Source:Clin Exp Dermatol; 34(1):20-5, 2009 Jan.
ISSN:1365-2230
Country of publication:England
Language:eng
Abstract:BACKGROUND: Many interventions have been described for inherited epidermolysis bullosa (EB), but it is unclear which are beneficial. AIMS: A systematic review of randomized controlled trials (RCTs) was performed to inform practice and highlight research gaps. METHODS: The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and the Cochrane Skin Group specialist library, from inception until 1 April 2007, were searched. Primary outcomes were healing of lesions or prevention of new lesions. Trials were assessed for quality of reporting and data were extracted. RESULTS: Five randomized double-blind placebo-controlled crossover studies were identified (n = 102). Two studies assessed oral tetracyclines in EB simplex (EBS). In one study (n = 12), 4/6 patients improved and 2/6 deteriorated on a dose of 1500 mg of tetracycline daily; only two patients completed the study. In the second study (n = 21), 6/18 and 7/18 improved on oxytetracycline 1 g and placebo, respectively. Two RCTs assessed topical interventions for EBS: aluminium chloride hexahydrate solution 20% (n = 23) and bufexamac cream 5% (n = 8). Neither showed a benefit over placebo. One RCT of 36 patients with recessive dystrophic EB compared phenytoin with placebo and failed to show any difference in mean lesion counts (difference = 0, 95% CI -11 to 4). CONCLUSIONS: There is no reliable trial evidence for interventions in inherited EB. In future, it may be that gene treatment becomes the best treatment approach for these diseases.
Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
Name of substance:0 (Aluminum Compounds); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Astringents); 0 (Chlorides); 0 (Tetracyclines); 3CYT62D3GA (aluminum chloride); 4T3C38J78L (Bufexamac)


  10 / 77 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text
PMID:18353041
Author:Belhadjali H; Ghannouchi N; Njim L; Mohamed M; Moussa A; Bayou F; Chakroun M; Zakhama A; Zili J
Address:Research Unit 22-08/UR/03, Department of Dermatology, Fattouma Bourguiba Hospital, Monastir, Tunisia. belhadjalihichem@yahoo.fr
Title:Acute generalized exanthematous pustulosis induced by bufexamac in an atopic girl.
Source:Contact Dermatitis; 58(4):247-8, 2008 Apr.
ISSN:1600-0536
Country of publication:England
Language:eng
Publication type:CASE REPORTS; JOURNAL ARTICLE
Name of substance:0 (Anti-Inflammatory Agents, Non-Steroidal); 4T3C38J78L (Bufexamac)



page 1 of 8 go to page                    
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information